Gwenn Hansen Sells 3,437 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Free Report) insider Gwenn Hansen sold 3,437 shares of Nurix Therapeutics stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total value of $83,519.10. Following the transaction, the insider now directly owns 50,670 shares in the company, valued at approximately $1,231,281. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Nurix Therapeutics Trading Down 4.5 %

Shares of NASDAQ NRIX traded down $1.13 during trading hours on Wednesday, hitting $24.07. 761,824 shares of the company traded hands, compared to its average volume of 885,869. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of -8.66 and a beta of 2.22. The company’s 50 day moving average price is $24.18 and its 200 day moving average price is $20.14. Nurix Therapeutics, Inc. has a 12 month low of $4.96 and a 12 month high of $27.60.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last released its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting the consensus estimate of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on NRIX shares. Robert W. Baird started coverage on Nurix Therapeutics in a report on Friday, September 6th. They issued an “outperform” rating and a $26.00 price target on the stock. HC Wainwright boosted their price target on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Jefferies Financial Group started coverage on Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 price target on the stock. UBS Group started coverage on Nurix Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Barclays boosted their price target on Nurix Therapeutics from $20.00 to $31.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $29.40.

Check Out Our Latest Analysis on NRIX

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds have recently bought and sold shares of NRIX. Amalgamated Bank grew its position in Nurix Therapeutics by 30.6% in the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after acquiring an additional 511 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares during the last quarter. GAMMA Investing LLC grew its position in Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after acquiring an additional 3,424 shares during the last quarter. International Assets Investment Management LLC grew its position in Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after acquiring an additional 4,119 shares during the last quarter. Finally, EntryPoint Capital LLC bought a new position in Nurix Therapeutics in the 1st quarter valued at $123,000.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Read More

Insider Buying and Selling by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.